



## Strattera® (atomoxetine) – First-time generic

- On May 30, 2017, several manufacturers received [FDA approval](#) for AB-rated generic versions of Eli Lilly's [Strattera \(atomoxetine\)](#).
  - [Teva](#), [Rising](#), and [Glenmark](#) immediately launched AB-rated generic versions of Strattera (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg) capsules.
  - [Prasco](#) launched an authorized generic version of Strattera.
  - Generic versions of Strattera from [Aurobindo](#) and [Apotex](#) were also approved.
- Strattera is indicated for the treatment of attention-deficit/hyperactivity disorder.
- Strattera carries a boxed warning for suicidal ideation in children and adolescents.
- 2016 [sales](#) for Strattera totaled \$854.7 million.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.